[Whitepaper] Gateways To Asia: Market Access In Japan And South Korea
Expanding to Asia can be a logical next step for pharma companies looking to grow beyond the mature markets of North America and Europe. Recent developments in market access and regulatory rules in Japan and South Korea have paved the way for such expansion, by introducing a newly consultative approach to clinical trials, lowering some of the barriers, shaving time off review processes, and otherwise making an entrée into the Asia markets a newly viable reality for pharma organizations.
In this Whitepaper, you will explore:
Japan’s PMDA services
Expedited review and conditional approval advancements
